Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOVID-E vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Dysfunctional uterine bleeding,Endometriosis
Prevention of pregnancy (FDA-approved)
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Metabolized via hepatic cytochrome P450 enzymes (CYP3A4) and conjugated with glucuronic acid and sulfate. Enterohepatic recirculation occurs.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethynodrel: 95-98% (albumin); mestranol: 97-99% (albumin and SHBG)
~99% bound to serum albumin and sex hormone-binding globulin.
Norethynodrel: 2-4 L/kg; mestranol: 3-5 L/kg; extensive tissue distribution
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: >90% for norethynodrel; mestranol: 40-60% (first-pass metabolism)
Oral: ~70% due to first-pass metabolism.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential fluid retention
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease (Child-Pugh class C); dose reduction recommended in moderate impairment (Child-Pugh class B: use lowest effective dose)
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not approved for use in pediatric patients; safety and efficacy not established
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No specific dose adjustment; caution due to increased risk of thromboembolic events and fluid retention in elderly patients
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events. Use contraindicated in women over 35 years who smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders, myocardial infarction, stroke, hepatic neoplasia, gallbladder disease, hypertension, and carbohydrate intolerance. Discontinue if jaundice, visual disturbances, or migraine occurs. Monitor blood pressure and liver function.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma, undiagnosed abnormal genital bleeding, known or suspected pregnancy, hepatic adenoma or carcinoma, impaired liver function, and smokers over 35 years.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions reported. Grapefruit juice may mildly increase estrogen levels but not clinically relevant. Maintain consistent dietary intake to avoid gastrointestinal upset.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects due to progestin and estrogen components. Second and third trimesters: Potential for feminization of male fetus, urogenital abnormalities, and possible long-term neurodevelopmental effects. Use contraindicated in pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk; M/P ratio not well established. Potential for adverse effects on infant including jaundice and breast enlargement. Avoid use during breastfeeding due to hormonal effects.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; do not use. No dosing adjustments applicable as use is avoided. If exposure occurs, discontinue immediately and manage supportively.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Enovid-E (5 mg norethynodrel, 0.075 mg mestranol) is a first-generation combined oral contraceptive. Due to high estrogen dose, increased risk of thromboembolism; avoid in smokers over 35 and those with migraine with aura. Typically prescribed for contraception or menstrual disorders. Monitor for breakthrough bleeding and hypertension.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time for 21 days, then 7 days off.,Do not smoke while taking this medication, especially if over 35.,Watch for signs of blood clots: sudden leg swelling, chest pain, shortness of breath.,Use backup contraception if you miss a pill, especially during the first week.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOVID-E vs AFIRMELLE, answered by our medical review team.
ENOVID-E is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOVID-E and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOVID-E is: 5 mg orally once daily for 20 days starting on day 5 of menstrual cycle. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOVID-E and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOVID-E is classified as Category C. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects due to progestin and estrogen components. Second and third trimesters: . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.